secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0000950170-25-059569
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q1 revenue $169M (+10% YoY); adjusted EPS $0.39 vs $0.30; orders up high-teens
--------------------------------------------------------------------------------

- Revenue $169M, up 10% reported, 14% organic non-COVID YoY; GAAP EPS $0.10, adjusted EPS $0.39.
- Adjusted operating income $23M, up 72% YoY; adjusted gross margin 53.7% vs 49.2%.
- Orders grew high-teens YoY with all four franchises up double-digits; biopharma and consumables record ex-COVID.
- FY2025 guidance reiterated: organic growth 9.5%-13.5%; adjusted EPS $1.63-$1.72.
- Closed acquisition of 908 Devices' bioprocessing portfolio; minimal tariff impact expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000095017025059569/0000950170-25-059569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000095017025059569/rgen-20250429.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-059569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer